Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series
Introduction Patients with chronic kidney disease usually have anemia secondary to an erythropoietin deficit. The emergence of biosimilar drugs of erythropoiesis-stimulating agents ensures broader access to these treatments. Objective This study analyzes the effectiveness of an epoetin α biosim...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN ES |
| Publicado: |
Medwave Estudios Limitada
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a2ce73468f3043b2a5060f8e35081468 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Introduction
Patients with chronic kidney disease usually have anemia secondary to an erythropoietin deficit. The emergence of biosimilar drugs of erythropoiesis-stimulating agents ensures broader access to these treatments.
Objective
This study analyzes the effectiveness of an epoetin α biosimilar drug in chronic kidney disease patients with anemia.
Methods
This observational retrospective study enrolled 111 consecutive outpatients with chronic kidney disease and anemia and criteria for using erythropoiesis-stimulating agents. We collected baseline epidemiological and comorbidity data, as well as hematological and renal function infor-mation. We analyzed the effectiveness of the biosimilar agent in naïve patients and those who already had other erythropoiesis-stimulating agents.
Results
The 111 included patients had a mean age of 83 ± 8 years, and 54% were males. We found that patients who previously received erythropoiesis-stimulating agents, maintained hemoglobin values at two months of treatment with the biosimilar, while the naïve group significantly raised their hemoglobin values (P < 0.001). Renal function remained stable within the whole sample. The cost of using erythropoiesis-stimulating agents was reduced by a mean of 82 ± 17% with the biosimilar drug.
Conclusion
Using a biosimilar of epoetin α is effective in patients with chronic kidney disease and anemia and significantly reduces costs. |
|---|